ii)
Elevated levels of the soluble form of bone marrow stromal cell
antigen 1 in the sera of patients with severe rheumatoid arthritis.
Lee-BO; Ishihara-K; Denno-K; Kobune-Y; Itoh-M; Muraoka-O; Kaisho-T;
Sasaki-T; Ochi-T; Hirano-T, Arthritis-Rheum. 1996 Apr; 39(4): 629-37
Bone marrow stromal cell antigen 1 (BST-1) is a novel glycosyl
phosphatidylinositol-anchored ectoenzyme, which is overexpressed on
bone marrow stromal and synovial cell lines derived from patients
with rheumatoid arthritis (RA). To investigate the pathophysiologic
roles of BST-1 in RA, we established an enzyme-linked immunosorbent
assay (ELISA) system to detect the soluble form of BST-1 (sBST-1) and
examined levels of sBST-1 in the sera of RA patients. METHODS:
Concentrations of sBST-1 in sera from healthy donors and from
patients with RA, osteoarthritis, Sjogren's syndrome, and systemic
lupus erythematosus were measured with the ELISA. RESULTS: In 7% of
the RA patient samples (10 of 143), concentrations of serum sBST-1
were higher (approximately 30-50-fold) than in non-RA samples. Serum
sBST-1 concentrations showed no correlation with age, C-reactive
protein level, or rheumatoid factor level. All RA patients with high
concentrations of serum sBST-1 had severe disease with involvement of
several large joints. CONCLUSION: We believe the measurement of serum
sBST-1 may have prognostic value, but further analysis is necessary
to clarify the clinical significance of elevated sBST-1 in RA.
|
|
|